Literature DB >> 8838146

Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate.

C Widmann1, W Dolci, B Thorens.   

Abstract

Glucagon-like peptide-1 (GLP-1) stimulates glucose-induced insulin secretion by binding to a specific G protein-coupled receptor linked to activation of the adenylyl cyclase pathway. Here, using insulinoma cell lines, we studied homologous and heterologous desensitization of GLP-1-induced cAMP production. Preexposure of the cells to GLP-1 induced a decrease in GLP-1-mediated cAMP production, as assessed by a 3- to 5-fold rightward shift of the dose-response curve and an approximately 20 percent decrease in the maximal production of cAMP. Activation of protein kinase C by the phorbol ester phorbol 12-myristate 13-acetate (PMA) also induced desensitization of the GLP-1-mediated response, leading to a 6- to 9-fold shift in the EC50 and a 30% decrease in the maximal production of cAMP. Both forms of desensitization were additive, and the protein kinase C inhibitor RO-318220 inhibited PMA-induced desensitization, but not agonist-induced desensitization. GLP-1- and PMA-dependent desensitization correlated with receptor phosphorylation, and the levels of phosphorylation induced by the two agents were additive. Furthermore, PMA-induced, but not GLP-1-induced, phosphorylation was totally inhibited by RO-318220. Internalization of the GLP-1 receptor did not participate in the desensitization induced by PMA, as a mutant GLP-1 receptor lacking the last 20 amino acids of the cytoplasmic tail was found to be totally resistant to the internalization process, but was still desensitized after PMA preexposure. PMA and GLP-1 were not able to induce the phosphorylation of a receptor deletion mutant lacking the last 33 amino acids of the cytoplasmic tail, indicating that the phosphorylation sites were located within the deleted region. The cAMP production mediated by this deletion mutant was not desensitized by PMA and was only poorly desensitized by GLP-1. Together, our results indicate that the production of cAMP and, hence, the stimulation of insulin secretion induced by GLP-1 can be negatively modulated by homologous and heterologous desensitization, mechanisms that involve receptor phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8838146     DOI: 10.1210/mend.10.1.8838146

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  15 in total

Review 1.  The structure and function of the glucagon-like peptide-1 receptor and its ligands.

Authors:  Dan Donnelly
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

3.  Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.

Authors:  Y Wang; R Perfetti; N H Greig; H W Holloway; K A DeOre; C Montrose-Rafizadeh; D Elahi; J M Egan
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

4.  Anchoring of protein kinase A facilitates hormone-mediated insulin secretion.

Authors:  L B Lester; L K Langeberg; J D Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

5.  Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.

Authors:  Nitika Arora Gupta; Jamie Mells; Richard M Dunham; Arash Grakoui; Jeffrey Handy; Neeraj Kumar Saxena; Frank A Anania
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

6.  A novel lipid-anchored A-kinase Anchoring Protein facilitates cAMP-responsive membrane events.

Authors:  I D Fraser; S J Tavalin; L B Lester; L K Langeberg; A M Westphal; R A Dean; N V Marrion; J D Scott
Journal:  EMBO J       Date:  1998-04-15       Impact factor: 11.598

Review 7.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects.

Authors:  P A Velasquez-Mieyer; P A Cowan; G E Umpierrez; R H Lustig; A K Cashion; G A Burghen
Journal:  Int J Obes Relat Metab Disord       Date:  2003-11

Review 10.  Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal.

Authors:  Simon A Hinke; Karine Hellemans; Frans C Schuit
Journal:  J Physiol       Date:  2004-06-04       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.